Investigator-assessed best response to acalabrutinib
| . | N = 134 . | |
|---|---|---|
| n/n . | % (95% CI*) or n (%) . | |
| ORR: CR + PR+ PRL | 94 (89, 97) | |
| ORR: CR + PR | 88 (81, 93) | |
| Best response | ||
| CR | 6 (4) | |
| PR | 112 (84) | |
| PRL | 8 (6) | |
| Stable disease | 2 (1) | |
| PD | 2 (1) | |
| Unknown† | 4 (3) | |
| ORR by high-risk subgroup: CR + PR + PRL | ||
| del(17)(p13.1) | 25/27 | 93 (76, 99) |
| del(11)(q22.3) | 20/21 | 95 (76, 100) |
| Unmutated IGHV | 77/81 | 95 (88, 99) |
| Complex karyotype, ≥3 abnormalities | 18/20 | 90 (68, 99) |
| . | N = 134 . | |
|---|---|---|
| n/n . | % (95% CI*) or n (%) . | |
| ORR: CR + PR+ PRL | 94 (89, 97) | |
| ORR: CR + PR | 88 (81, 93) | |
| Best response | ||
| CR | 6 (4) | |
| PR | 112 (84) | |
| PRL | 8 (6) | |
| Stable disease | 2 (1) | |
| PD | 2 (1) | |
| Unknown† | 4 (3) | |
| ORR by high-risk subgroup: CR + PR + PRL | ||
| del(17)(p13.1) | 25/27 | 93 (76, 99) |
| del(11)(q22.3) | 20/21 | 95 (76, 100) |
| Unmutated IGHV | 77/81 | 95 (88, 99) |
| Complex karyotype, ≥3 abnormalities | 18/20 | 90 (68, 99) |